$3.2 million per dose Elevidys fails to meet primary endpoint in phase 3 trial

Published Date: 23 Oct 2024

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy, did not achieve its primary endpoint, according to findings published in Nature Medicine. A News ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nuclear missile workers are contracting cancer: They blame the bases

2.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

3.

New analysis helps discern benign from malignant thyroid growths

4.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot